IDE-397
- Generic Name
- IDE-397
A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- MTAP-null Non-Small-Cell Lung CancerMTAP-null Solid Tumors
- Interventions
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 53
- Registration Number
- NCT05975073
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇺🇸Astera Cancer Care, East Brunswick, New Jersey, United States
🇪🇸Hospital Universitari Vall d Hebron, Barcelona, Cataluña, Spain
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
Phase 1
Recruiting
- Conditions
- Solid Tumor
- Interventions
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- IDEAYA Biosciences
- Target Recruit Count
- 180
- Registration Number
- NCT04794699
- Locations
- 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸City of Hope, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath